Gan, C. L., Stukalin, I., Meyers, D. E., Dudani, S., Grosjean, H. A. I., Dolter, S., Ewanchuk, B. W., Goutam, S., Sander, M., Wells, C., Pabani, A., Cheng, T., Monzon, J., Morris, D., Basappa, N. S., Pal, S. K., Wood, L. A., Donskov, F., Choueiri, T. K., & Heng, D. Y. C. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer, 151, 115-125. https://doi.org/10.1016/j.ejca.2021.04.004
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. / Gan, Chun L.; Stukalin, Igor; Meyers, Daniel E. et al.
In:
European Journal of Cancer, Vol. 151, 07.2021, p. 115-125.
Research output: Contribution to journal › Article › peer-review
Gan, CL, Stukalin, I, Meyers, DE, Dudani, S, Grosjean, HAI, Dolter, S, Ewanchuk, BW, Goutam, S, Sander, M, Wells, C, Pabani, A, Cheng, T, Monzon, J, Morris, D, Basappa, NS, Pal, SK, Wood, LA, Donskov, F, Choueiri, TK & Heng, DYC 2021, 'Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials', European Journal of Cancer, vol. 151, pp. 115-125. https://doi.org/10.1016/j.ejca.2021.04.004
Gan CL, Stukalin I, Meyers DE, Dudani S, Grosjean HAI, Dolter S et al. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 2021 Jul;151:115-125. doi: 10.1016/j.ejca.2021.04.004
Gan, Chun L. ; Stukalin, Igor ; Meyers, Daniel E. et al. / Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. In: European Journal of Cancer. 2021 ; Vol. 151. pp. 115-125.
@article{28410ab027d94611913af164b68e98be,
title = "Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials",
keywords = "Clinical outcomes, Clinical trial ineligible, IMDC, Immuno-oncology, Immunotherapy, Melanoma, Non–small-cell lung cancer, Real-world patients, Renal cell carcinoma, Trial eligibility",
author = "Gan, {Chun L.} and Igor Stukalin and Meyers, {Daniel E.} and Shaan Dudani and Grosjean, {Heidi A.I.} and Samantha Dolter and Ewanchuk, {Benjamin W.} and Siddhartha Goutam and Michael Sander and Connor Wells and Aliyah Pabani and Tina Cheng and Jose Monzon and Don Morris and Basappa, {Naveen S.} and Pal, {Sumanta K.} and Wood, {Lori A.} and Frede Donskov and Choueiri, {Toni K.} and Heng, {Daniel Y.C.}",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = jul,
doi = "10.1016/j.ejca.2021.04.004",
language = "English",
volume = "151",
pages = "115--125",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
}
TY - JOUR
T1 - Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials
AU - Gan, Chun L.
AU - Stukalin, Igor
AU - Meyers, Daniel E.
AU - Dudani, Shaan
AU - Grosjean, Heidi A.I.
AU - Dolter, Samantha
AU - Ewanchuk, Benjamin W.
AU - Goutam, Siddhartha
AU - Sander, Michael
AU - Wells, Connor
AU - Pabani, Aliyah
AU - Cheng, Tina
AU - Monzon, Jose
AU - Morris, Don
AU - Basappa, Naveen S.
AU - Pal, Sumanta K.
AU - Wood, Lori A.
AU - Donskov, Frede
AU - Choueiri, Toni K.
AU - Heng, Daniel Y.C.
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/7
Y1 - 2021/7
KW - Clinical outcomes
KW - Clinical trial ineligible
KW - IMDC
KW - Immuno-oncology
KW - Immunotherapy
KW - Melanoma
KW - Non–small-cell lung cancer
KW - Real-world patients
KW - Renal cell carcinoma
KW - Trial eligibility
UR - http://www.scopus.com/inward/record.url?scp=85105516700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105516700&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2021.04.004
DO - 10.1016/j.ejca.2021.04.004
M3 - Article
C2 - 33975059
AN - SCOPUS:85105516700
SN - 0959-8049
VL - 151
SP - 115
EP - 125
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -
